Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 first-in-human dose-escalation study of talquetamab in relapsed or refractory multiple myeloma (Japan extension)
jRCT2031210621Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Response Rate (ORR). Started Jul 2022; status: completed.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031210621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210621.